4OR.F - Organovo Holdings, Inc.
| Previous Close | 0.2531 |
| Open | 0.2562 |
| Bid | 0.2565 x 200000 |
| Ask | 0.2664 x 200000 |
| Day's Range | 0.2562 - 0.2654 |
| 52 Week Range | 0.2247 - 1.1500 |
| Volume | 600 |
| Avg. Volume | 9,110 |
| Market Cap | 35.615M |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Motley FoolOrganovo Holdings (ONVO) Q3 2019 Earnings Conference Call Transcript
ONVO earnings call for the period ending December 31, 2018.
- Associated Press
Organovo: Fiscal 3Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- Zacks
Organovo (ONVO) Reports Q2 Loss, Tops Revenue Estimates
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Organovo: Fiscal 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 5 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...
- Benzinga
Organovo Q2 Earnings Preview
On Thursday, Nov. 8, Organovo Holdings (NYSE: ONVO ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street ...
- Simply Wall St.
Is Organovo Holdings Inc’s (NASDAQ:ONVO) Balance Sheet A Threat To Its Future?
The direct benefit for Organovo Holdings Inc (NASDAQ:ONVO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
